Trial Profile
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2016
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 19 May 2014 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 27 Feb 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 13 Sep 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.